Global Industry Analysts, Inc., Oct 2006, Pages: 387
(France) II-42
Schering AG (Germany) II-42
9. Global Market Perspective II-43
Table 12: World Recent Past, Current & Future Analysis for
ColorectalCancer Therapeutics by Geographic Region/Country
Global Industry Analysts, Inc., Oct 2011, Pages: 897
Company Limited (Japan) 140
Takeda's Oncology Pipeline (As of 2011) 141
15. GLOBAL MARKET PERSPECTIVE 142
Table 24: Global Recent Past, Current & Future Analysis for
Cancer Therapies by Geographic
Global Industry Analysts, Inc., Feb 2011, Pages: 682
. EUROPE 148
A.Market Analysis 148
Facet of Angiogenesis in the European Market 148
Angiogenesis Market - A Historic Perspective 148
Cancer Trends 148
Table 26: Cancer Incidence in Europe by Site (2009
GBI Research, May 2011, Pages: 93
. The A provides an in-depth analysis of the trials conducted by major pharmaceutical companies for the top five oncology therapeutic indications, which are breast cancer, colorectalcancer, prostate cancer, lung
Global Industry Analysts, Inc., Oct 2011, Pages: 284
in performing common surgical procedures, and in diagnosing cancer and other diseases. Endoscopically performed procedures are less invasive and offer significant cost savings in terms of pre and post operative
Global Industry Analysts, Inc., Oct 2010, Pages: 360
Cost of Radiation Therapy 55
Limitations of Conventional Radiation Therapy Techniques 56
9. CANCER TREATMENT - A COSTANALYSIS
Global Industry Analysts, Inc., Aug 2011, Pages: 1305
to growing number of cancer biomarkers receiving regulatory clearances. Cardiology is expected to emerge as the fastest growing segment in terms of therapeutics with a CAGR of about 24% over the analysis
Global Industry Analysts, Inc., Oct 2006, Pages: 563
Perspective for Breast Cancer
Therapeutics by Product Segment- Hormonal Therapy and
Chemotherapy Markets for 2000, 2006, and 2010 III-53
2f. Rest of Europe III-54
A.Market Analysis III-54
Highlights III
GBI Research, Feb 2010, Pages: 76
“Biomarkers In Drug Discovery - Optimizing Drug Discovery Timeline and Costs”. The report provides an in-depth analysis of the potential applications of biomarkers in pharmaceutical drug discovery
TriMark Publications, July 2011, Pages: 201
to Predictive Medicine
6.28 Analysis of Cost-Effectiveness at the Individual Level
6.29 The Patient and Advocate Perspective: An Evolution of Influence
6.30 Real-World Experiences Translating the Vision
Bioseeker, Jan 2007, Pages: 750
this analysis to drive strategic planning decisions in oncology drug development TOP 7 CANCER INDICATIONS
THERAPEUTIC & COMPETITIVE INSIGHTS
1 EXECUTIVE SUMMARY
2 TABLE OF CONTENTS
21 LIST BOXES
22 LIST
Global Industry Analysts, Inc., Jan 2011, Pages: 354
Testing
Pharmacogenetics/Pharmacogenomics
Review of Select Genetic Tests
Cystic Fibrosis
Breast and Ovarian Cancer
Alzheimers Disease
ColorectalCancer
Haemochromatosis (HH)
Cowden Syndrome
Global Industry Analysts, Inc., Oct 2010, Pages: 507
65
Presence of Estrogen in OCs Offers Protection from ColorectalCancer 65
Hormonal Contraceptive Usage & Risk
